These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
561 related articles for article (PubMed ID: 22529186)
21. Hypoxia induces CD133 expression in human lung cancer cells by up-regulation of OCT3/4 and SOX2. Iida H; Suzuki M; Goitsuka R; Ueno H Int J Oncol; 2012 Jan; 40(1):71-9. PubMed ID: 21947321 [TBL] [Abstract][Full Text] [Related]
22. Increased expression of CD133 is a strong predictor of poor outcome in stage I colorectal cancer patients. Reggiani Bonetti L; Migaldi M; Caredda E; Boninsegna A; Ponz De Leon M; Di Gregorio C; Barresi V; Scannone D; Danese S; Cittadini A; Sgambato A Scand J Gastroenterol; 2012 Oct; 47(10):1211-7. PubMed ID: 22856425 [TBL] [Abstract][Full Text] [Related]
23. The combination of stem cell markers CD133 and ABCG2 predicts relapse in stage I non-small cell lung carcinomas. Li F; Zeng H; Ying K Med Oncol; 2011 Dec; 28(4):1458-62. PubMed ID: 20717756 [TBL] [Abstract][Full Text] [Related]
24. Expressions of putative cancer stem cell markers ABCB1, ABCG2, and CD133 are correlated with the degree of differentiation of gastric cancer. Jiang Y; He Y; Li H; Li HN; Zhang L; Hu W; Sun YM; Chen FL; Jin XM Gastric Cancer; 2012 Oct; 15(4):440-50. PubMed ID: 22395309 [TBL] [Abstract][Full Text] [Related]
25. Prognostic significance of CTCs and CSCs of tumor drainage vein blood in Dukes' stage B and C colorectal cancer patients. Shimada R; Iinuma H; Akahane T; Horiuchi A; Watanabe T Oncol Rep; 2012 Apr; 27(4):947-53. PubMed ID: 22267181 [TBL] [Abstract][Full Text] [Related]
26. Putative stemness markers octamer-binding transcription factor 4, sex-determining region Y-box 2, and NANOG in non-small cell lung carcinoma: A clinicopathological association. Upadhyay VA; Shah KA; Makwana DP; Raval AP; Shah FD; Rawal RM J Cancer Res Ther; 2020; 16(4):804-810. PubMed ID: 32930122 [TBL] [Abstract][Full Text] [Related]
27. Expression of CD133 and other putative stem cell markers in uveal melanoma. Thill M; Berna MJ; Grierson R; Reinhart I; Voelkel T; Piechaczek C; Galambos P; Jager MJ; Richard G; Lange C; Gehling UM Melanoma Res; 2011 Oct; 21(5):405-16. PubMed ID: 21900792 [TBL] [Abstract][Full Text] [Related]
28. Colon cancer stem cell markers CD44 and CD133 in patients with colorectal cancer and synchronous hepatic metastases. Jing F; Kim HJ; Kim CH; Kim YJ; Lee JH; Kim HR Int J Oncol; 2015 Apr; 46(4):1582-8. PubMed ID: 25625240 [TBL] [Abstract][Full Text] [Related]
29. Expression and clinical significance of the stem cell marker CD133 in hepatocellular carcinoma. Song W; Li H; Tao K; Li R; Song Z; Zhao Q; Zhang F; Dou K Int J Clin Pract; 2008 Aug; 62(8):1212-8. PubMed ID: 18479363 [TBL] [Abstract][Full Text] [Related]
30. Expressions and clinical significances of CD133 protein and CD133 mRNA in primary lesion of gastric adenocacinoma. Yu JW; Zhang P; Wu JG; Wu SH; Li XQ; Wang ST; Lu RQ; Ni XC; Jiang BJ J Exp Clin Cancer Res; 2010 Nov; 29(1):141. PubMed ID: 21054902 [TBL] [Abstract][Full Text] [Related]
31. Expression of nestin, CD133 and ABCG2 in relation to the clinical outcome in pediatric sarcomas. Zambo I; Hermanova M; Zapletalova D; Skoda J; Mudry P; Kyr M; Zitterbart K; Sterba J; Veselska R Cancer Biomark; 2016 Jun; 17(1):107-16. PubMed ID: 27314299 [TBL] [Abstract][Full Text] [Related]
32. The cancer stem cell antigens CD133, BCRP1/ABCG2 and CD117/c-KIT are not associated with prognosis in resected early-stage non-small cell lung cancer. Herpel E; Jensen K; Muley T; Warth A; Schnabel PA; Meister M; Herth FJ; Dienemann H; Thomas M; Gottschling S Anticancer Res; 2011 Dec; 31(12):4491-500. PubMed ID: 22199321 [TBL] [Abstract][Full Text] [Related]
33. Prognostic value of Musashi-1 in endometrioid adenocarcinoma. Ma L; Xu YL; Ding WJ; Shao HF; Teng YC Int J Clin Exp Pathol; 2015; 8(5):4564-72. PubMed ID: 26191146 [TBL] [Abstract][Full Text] [Related]
34. Cancer stem cell marker CD133+ tumour cells and clinical outcome in rectal cancer. Wang Q; Chen ZG; Du CZ; Wang HW; Yan L; Gu J Histopathology; 2009 Sep; 55(3):284-93. PubMed ID: 19723143 [TBL] [Abstract][Full Text] [Related]
35. Expression of aldehyde dehydrogenase and CD133 defines ovarian cancer stem cells. Kryczek I; Liu S; Roh M; Vatan L; Szeliga W; Wei S; Banerjee M; Mao Y; Kotarski J; Wicha MS; Liu R; Zou W Int J Cancer; 2012 Jan; 130(1):29-39. PubMed ID: 21480217 [TBL] [Abstract][Full Text] [Related]
36. The prognostic value of clinical factors and cancer stem cell-related markers in gliomas. Dahlrot RH Dan Med J; 2014 Oct; 61(10):B4944. PubMed ID: 25283629 [TBL] [Abstract][Full Text] [Related]
37. Expression of cancer stem cell markers in pancreatic intraepithelial neoplasias and pancreatic ductal adenocarcinomas. Kure S; Matsuda Y; Hagio M; Ueda J; Naito Z; Ishiwata T Int J Oncol; 2012 Oct; 41(4):1314-24. PubMed ID: 22824809 [TBL] [Abstract][Full Text] [Related]
38. Elevated circulating endothelial progenitor marker CD133 messenger RNA levels predict colon cancer recurrence. Lin EH; Hassan M; Li Y; Zhao H; Nooka A; Sorenson E; Xie K; Champlin R; Wu X; Li D Cancer; 2007 Aug; 110(3):534-42. PubMed ID: 17594720 [TBL] [Abstract][Full Text] [Related]
39. Prognostic impact of CD133 mRNA expression in 48 glioblastoma patients treated with concomitant radiochemotherapy: a prospective patient cohort at a single institution. Metellus P; Nanni-Metellus I; Delfino C; Colin C; Tchogandjian A; Coulibaly B; Fina F; Loundou A; Barrie M; Chinot O; Ouafik L; Figarella-Branger D Ann Surg Oncol; 2011 Oct; 18(10):2937-45. PubMed ID: 21479688 [TBL] [Abstract][Full Text] [Related]
40. Inflammation-related DNA damage and expression of CD133 and Oct3/4 in cholangiocarcinoma patients with poor prognosis. Thanan R; Pairojkul C; Pinlaor S; Khuntikeo N; Wongkham C; Sripa B; Ma N; Vaeteewoottacharn K; Furukawa A; Kobayashi H; Hiraku Y; Oikawa S; Kawanishi S; Yongvanit P; Murata M Free Radic Biol Med; 2013 Dec; 65():1464-1472. PubMed ID: 23917144 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]